This past year, emerging evidence from exome and RNA-sequencing data suggests that FBXO11-inactivating mutations occur in de novo AML12, supporting our model of FBXO11 as a tumor suppressor in myeloid malignancies. This evidence concerns the gene FBXO11 and neoplasm.